1). While a moderate reduction was observed for MHC II, detection of its ligand, TCRαβ, remained unchanged (Fig. 5, Table 1). Detection of CD28, B7.1, and B7.2, which are involved in the generation of costimulatory signals for T cells, was significantly reduced by EGCG treatment (Fig. 5, Table 1). Greater reduction was also shown in CD49d, an adhesion molecule (Table 1).

Unresponsiveness of Responder T Cells Prestimulated With EGCG-Treated Stimulator Cells

To analyze whether reduced T-cell responses after EGCG treatment are reversed by secondary stimulation with fresh stimulator cells or exogenous IL-2, after one-way MLR cultures we restimulated MLR cells with


Figure 5. Flow cytometric analysis of cell surface molecules after EGCG treatment. C57Bl/6 splenocytes were either untreated or treated with EGCG (200 and 400 μM/10^7 cells), and then stained by epitope-specific monoclonal antibodies. A minimum of 10,000 counts per samples was analyzed by FACScan, and the representative results are shown.

EGCG-untreated fresh stimulator cells or IL-2 (1.7 U/ml) and analyzed the T-cell proliferation in secondary cultures. There was significant suppression of T-cell proliferation down to or below that of the unstimulated control cultures (Fig. 6).

Detection of Apoptosis by Cytometry

To examine the proportions of apoptotic cells in responder cells (C57Bl/6) and EGCG-treated stimulator cells (BALB/c), cells from MLR cultures after 24 h were analyzed by Annexin V assay. For the responder cells that were cocultured with the stimulator cells treated with EGCG, there was no substantial change in the proportion of apoptotic cells due to the EGCG treatment (0 μM: 81.8 ± 2.1%; 200 μM: 77.9 ± 1.1%; 400 μM: 78.7 ± 1.7%, based on one-way ANOVA of triplicate samples, $F = 4.43, p > 0.05$) (Fig. 7). In contrast, for the stimulator cells, the proportion of apoptotic cells significantly decreased with the EGCG treatment (Fig. 7).

DISCUSSION

Our present study demonstrated that EGCG can prevent allostimulation in a murine in vitro allograft context. EGCG treatment of murine splenocytes decreased the cell signaling for optimal allostimulation and attenuated the activation and proliferation of T cells in the MLR cultures.


Figure 6. Unresponsiveness of responder T cells that have been prestimulated with EGCG-treated stimulator cells. After coculturing C57Bl/6 splenocytes with EGCG-treated BALB/c splenocytes for 48 h, MLR wells were restimulated with either fresh untreated BALB/c splenocytes (black columns) or exogenous IL-2 (hatched columns), and incubated for an additional 48 h. C57Bl/6 without any stimulation is shown as a background (blank column). Differences were significant between untreated and treated groups (200 or 400 μM/10^7 cells) for cell-stimulated cultures ($p < 0.0001$) and IL-2-stimulated cultures ($p < 0.0001$).

Tissue or organ transplantation is increasingly applied for the treatment of many medical problems, but its major drawbacks are transplant rejection and GVHD. One of the ordinary therapeutic methods to prevent these problems is the application of pharmacological agents that suppress T-cell activation (18). Although these chemical agents mitigate the problems by inhibiting T-cell signaling and activation, they often cause significant side effects on various tissues such as renal, hepatic, gastrointestinal, and mucosal systems (3). To avoid these side effects, more amenable methods have been developed (10,11,14). One of the promising methods is immunocamouflage where the donor tissues bearing cell surface antigenic determinants are coated with nonimmunogenic agents such as polyethylene glycol (PEG) (14). PEG can block immunogenic recognition by the host immune system and decrease graft rejection and GVHD (4,13). In the present study, we hypothesized that a tea polyphenol, EGCG, also blocks antigenic determinants and attenuates the allostimulation and subsequent activation of host T cells.

Our results indicate that responder T-cell proliferation in the MLR culture was attenuated when the stimulator cells were treated with EGCG (Fig. 1). The EGCG treatment of the stimulator cells representing the transplant led to the attenuation of T-cell proliferation of the responder cells (Fig. 4) representing the host, which is usually targeted by immunosuppressive drugs. Because the stimulator cells in one-way MLR culture had been arrested of proliferation by mitomycin C, the decrease of T-cell proliferation was largely due to the influence of EGCG on the stimulator cells and/or their stimulatory activities. The choice of C57Bl/6 as the responder rather than the stimulator in the one-way MLR in these experiments was to avoid overestimating the attenuating potential of EGCG treatment because C57Bl/6 T cells are classified as Th-1 type and are generally considered to have stronger and more sustained response toward cellular antigens than BALB/c T cells, which belong to Th-2 type.

It must be noted that the decrease of T-cell proliferation was not due to the direct toxicity of EGCG on the stimulator cells. In fact, EGCG-treated stimulator cells in MLR cultures had reduced levels of apoptosis than untreated controls (Fig. 7). For the same reason, the production of IL-2 in the one-way MLR cultures decreased supposedly due to the reduced stimulation of T cells (Fig. 3) by the EGCG-treated stimulator cells but not loss of viability of the latter. IL-2 production was also reduced in two-way MLR cultures (Fig. 3). In two-way MLR cultures, we cannot simply determine which cell type (C57B/6 or BALB/c) is actually contributing to IL-2 production, and this reduction seemed assigned to the inactivation of both responder and stimulator T cells,

Figure 7. Analysis of apoptosis in responder and EGCG-treated stimulator cells in the MLR culture. C57Bl/6 splenocytes were cocultured with EGCG-treated BALB/c splenocytes for 24 h, and cultured cells were stained with PE-conjugated anti-mouse H-2K^b and FITC-conjugated Annexin V. The upper figures show three representative scatter grams (lower left quadrant: nonapoptotic stimulator; lower right quandrant: apoptotic stimulator; upper left quadrant: nonapoptotic responder; upper right quadrant: apoptotic responder cell populations). The lower graph shows the proportions of stimulator cell populations treated with 0, 200, or 400 µM EGCG before MLR culture with responder cells.

because activation of stimulator (BALB/c) T cells was also attenuated by the treatment with EGCG (our unpublished results).

The T cells stimulated with EGCG-treated stimulators were not only attenuated of proliferation but rendered somehow unresponsive toward allostimulation (i.e., they were in an anergic state). In fact, the proliferation of the responder cells did not recover upon secondary stimulation with fresh stimulator cells or even exogenous IL-2 (Fig. 6). The lack of responsiveness to the secondary stimulation with cells is not necessarily due to the mortality of responder cells, as indicated by the result of apoptosis detection (Fig. 7). Although T-cell apoptosis is known to be required in the induction of peripheral transplantation tolerance (20), the level of responder cell apoptosis occurring in our experimental system suggests that the induction of anergy due to EGCG treatment of stimulator cells is involved in the unresponsiveness of responder T cells (Fig. 7) Furthermore, the lack of responsiveness to the secondary stimu-

lation with exogenous IL-2, in turn, suggests that the stimulation of CD8$^+$ T cells may be prevented by the stimulation with EGCG-treated stimulators. These results provide further evidence to support that EGCG treatment prevents acute graft rejection (7) and present a question as to what mechanisms are involved in the influence of EGCG on the stimulator cells and their activities.

In light of the present hypothesis, the simplest interpretation is that stimulatory activities were abrogated by blocking cell surface molecules with EGCG, resulting in weak or incomplete stimulation of alloreactive T cells. Indeed, staining intensity of cell surface molecules involved in allorecognition, costimulation, and cell-to-cell adhesion were reduced by the EGCG treatment (Table 1). Weakening or blockage of interactions of any of these molecules and their ligands could lead to incomplete activation of T cells (4).

Particular attention is paid to the different effects exhibited among these cell surface molecules. Normally,

T cell is stimulated at an allorecognition site that consti-
tutes a main recognition domain of T-cell receptor
(TCR) that binds to a complex formed by a foreign pep-
tide and a major histocompatibility complex class I or II
(MHC I or II) molecule. As the results of surface marker
analysis indicate, on one hand, EGCG treatment moder-
ately reduced the detection of MHC I and II molecules
but not that of TCRαβ (Fig. 5, Table 1). On the other
hand, EGCG treatment strongly reduced the detection of
costimulatory molecules B7.1 (CD80) and B7.2 (CD86)
as well as their ligand, CD28 (Fig. 5, Table 1), indicat-
ing potential abrogation of pivotal costimulatory signals
(6,8,15–17) that may lead to the induction of anergic
state in T cells. The detection of adhesion molecule,
CD49d, was also strongly reduced, suggesting weaken-
ing of cell-to-cell adhesion prerequisite to allostimula-
tion (Table 1).

Besides the anergy induction, other modes of action
of EGCG can be suggested with respect to its possible
influence on antigen-presenting cells. The EGCG mole-
cules, with their amphipathic property depending on
treatment conditions, are considered to penetrate the cell
membrane and interfere with specific biochemical path-
ways underlying cell activation processes. For example,
EGCG is known to downregulate the activity of NF-κB,
which is involved in the activation of macrophages and
dendritic cells (1,9). In addition, there is a large number
of cytokines that are involved in the activation of anti-
gen-presenting cells, and EGCG may influence the ac-
tivity or production of these cytokines. EGCG may not
only influence these indirect immunosuppressions but
also the direct suppression by means of regulatory T cells.

The EGCG treatment presented in this study can pro-
vide a novel and useful method to prevent allorejection
of foreign tissues, because donor tissues are simply to
be immersed in culture media containing EGCG before
being transplanted to a recipient body system. In terms
of its potential clinical application, this plant-derived
agent is expected to require less preclinical toxicological
tests and lower manufacturing costs than synthetic
chemicals. Regarding dose–effect comparison, EGCG
dosage used in the present study was somewhat higher
than that of methylated PEG, but the overall level of the
attenuation effect was in a similar range to that reported
for PEG-camouflaged cells (4). Although further investi-
gation is necessary with respect to the mechanisms be-
hind the immunosuppressive actions, the treatment of
donor tissues with EGCG may have a potential value for
the prevention of allorejection and can be applicable in
other transplantation situations.

REFERENCES

1. Ahn, S.; Kim, G.; Kim, J.; Baik, S.; Han, M.; Lee, H.;
    Moon, D.; Lee, C.; Kang, J.; Kim, B.; Oh, Y.; Yang, H.;
    Park, Y. Epigallocatechin-3-gallate, constituent of green
    tea, suppresses the LPS-induced phenotypic and func-
    tional maturation of murine dendritic cells through inhibi-
    tion of mitogen-activated protein kinases and NF-κB. Bio-
    chem. Biophys. Res. Commun. 313:148–155; 2004.
2. Ashida, H.; Fukuda, I.; Yamashita, T.; Kanazawa, K. Fla-
    vones and flavonols at dietary levels inhibit a transforma-
    tion of aryl hydrocarbon receptor induced by dioxin.
    FEBS Lett. 476:213–217; 2000.
3. Askenasy, N.; Yolcu, E. S.; Yaniv, I.; Shirwan, H. Induc-
    tion of tolerance using Fas ligand: A double-edged immu-
    nomodulator. Blood 105:1396–1404; 2005.
4. Chen, A. M.; Scott, M. D. Immunocamouflage: Preven-
    tion of transfusion-induced graft-versus-host disease via
    polymer grafting of donor cells. J. Biomed. Mater. Res.
    67A:626–636; 2003.
5. Fidler, J. M.; Ku, G.; Piazza, D.; Xu, R.; Jin, R.; Chen, Z.
    Immunosuppressive activity of the Chinese medicinal
    plant Tripterygium wilfordii. III. Suppression of graft-
    versus-host disease in murine allogeneic bone marrow
    transplantation by the PG27 extract. Transplantation 74:
    445–457; 2002.
6. Gudmundsdottir, H.; Turka, L. A. T-cell costimulatory
    blockade: New therapies for transplant rejection. J. Am.
    Soc. Nephrol. 10:1356–1365; 1999.
7. Ikeguchi, R.; Kakinoki, R.; Matsumoto, T.; Hyon, S.;
    Nakamura, T. Peripheral nerve allografts stored in green
    tea polyphenol solution. Transplantation 79:688–695; 2005.
8. Kurlberg, G.; Haglind, E.; Schön, K.; Törnqvist, H.;
    Lycke, N. Blockade of the B7-CD28 pathway by
    CTLA4?Ig counteracts rejection and prolongs survival in
    small bowel transplantation. Scand. J. Immunol. 51:224–
    230; 2000.
9. Lin, Y.; Tsai, S.; Lin-Shiau, S.; Ho, C.; Lin, J. Theaflavin-
    3,3′-digallate from black tea blocks the nitric oxide syn-
    thase by down-regulating the activation of NF-kappa B in
    macrophages. Eur. J. Pharmacol. 367:379–388; 1999.
10. Murphy, W. J.; Blazar, B. R. New strategies for prevent-
    ing graft-versus-host disease. Curr. Opin. Immunol. 11:
    509–515; 1999.
11. Noguchi, H.; Matsushita, M.; Okitsu, T.; Moriwaki, A.;
    Tomizawa, K.; Kang, S.; Li, S.; Kobayashi, N.; Matsu-
    moto, S.; Tanaka, K.; Tanaka, N.; Matsui, H. A new cell-
    permeable peptide allows successful allogeneic islet trans-
    plantation in mice. Nat. Med. 10:305–309; 2004.
12. Sazuka, M.; Itoi, T.; Suzuki, Y. Evidence for the interac-
    tion between (–)-epigallocatechin gallate and human
    plasma proteins fibronectin, fibrinogen, and histidine-rich
    glycoprotein. Biosci. Biotech. Biochem. 60:1317–1319;
    1996.
13. Scott, M. D.; Chen, A. M. Beyond the red cell: Pegylation
    of other blood cells and tissues. Transf. Clin. Biol. 11:
    40–46; 2004.
14. Scott, M. D.; Murad, K. L.; Koumpouras, F.; Talbot, M.;
    Eaton, J. W. Chemical camouflage of antigenic determi-
    nants: 'Stealth' erythrocytes. Proc. Natl. Acad. Sci. USA
    94:7566–7571; 1997.

15. Schwartz, R. H. T cell anergy. Ann. Rev. Immunol. 21: 305–334; 2003.
16. Turka, L. A.; Linsley, P. S.; Lin, H.; Brady, W.; Leiden, J. M.; Wei, R.; Gibson, M. L.; Zheng, X.; Myrdal, S.; Gordon, D.; Bailey, T.; Bolling, S. F.; Thompson, C. B. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89:11102–11105; 1992.
17. Vacchio, M. S.; Hodes, R. J. CD28 costimulation is required for in vivo induction of peripheral tolerance in CD8 T cells. J. Exp. Med. 197:19–26; 2003.
18. Walsh, P. T.; Taylor, D. K.; Turka, L. A. Tregs and transplantation tolerance. J. Clin. Invest. 114:1398–1403; 2004.
19. Wang, X.; Sun, H.; Chen, G.; Liu, W.; Wise, Y.; Yung, C.; Sudo, Y.; Tamura, K.; Garcia, B.; Zhong, R. Immunosuppression with a combination of PG490-88 and a subtherapeutic dose of FK506 in a canine renal allograft model. Transplantation 79:1537–1544; 2005.
20. Wells, A. D.; Li, X. C.; Li, Y.; Walsh, M. C.; Zheng, X. X.; Wu, Z.; Nunez, G.; Tang, A.; Sayegh, M.; Hancock, W. W.; Strom, T. B.; Turka, L. A. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5:1303–1307; 1999.
21. Wilasrusmee, C.; Siddiqui, J.; Bruch, D.; Wilasrusmee, S.; Kittur, S.; Kittur, D. In vitro immunomodulatory effects of herbal products. Am. Surg. 68:860–864; 2002.

Pancreas preservation for pancreas and islet transplantation

Yasuhiro Iwanaga[a,b], David E.R. Sutherland[b], James V. Harmon[b] and Klearchos K. Papas[b]

[a]Transplantation Unit, Kyoto University Hospital, Kyoto, Japan and [b]Department of Surgery, Division of Transplantation, University of Minnesota, Minneapolis, USA

Correspondence to David E.R. Sutherland, MD, PhD, Department of Surgery, University of Minnesota, MMC 280, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Tel: +1 612 625 7600; e-mail: dsuther@umn.edu

Current Opinion in Organ Transplantation 2008, 13:445–451

Purpose of review
To summarize advances and limitations in pancreas procurement and preservation for pancreas and islet transplantation, and review advances in islet protection and preservation.

Recent findings
Pancreases procured after cardiac death, with in-situ regional organ cooling, have been successfully used for islet transplantation. Colloid-free Celsior and histidine-tryptophan-ketoglutarate preservation solutions are comparable to University of Wisconsin solution when used for cold storage before pancreas transplantation. Colloid-free preservation solutions are inferior to University of Wisconsin solution for pancreas preservation prior to islet isolation and transplantation. Clinical reports on pancreas and islet transplants suggest that the two-layer method may not offer significant benefits over cold storage with the University of Wisconsin solution: improved oxygenation may depend on the graft size; benefits in experimental models may not translate to human organs. Improvements in islet yield and quality occurred from pancreases treated with inhibitors of stress-induced apoptosis during procurement, storage, isolation or culture. Pancreas perfusion may be desirable before islet isolation and transplantation and may improve islet yields and quality. Methods for real-time, noninvasive assessment of pancreas quality during preservation have been implemented and objective islet potency assays have been developed and validated. These innovations should contribute to objective evaluation and establishment of improved pancreas preservation and islet isolation strategies.

Summary
Cold storage may be adequate for preservation before pancreas transplants, but insufficient when pancreases are processed for islets or when expanded donors are used. Supplementation of cold storage solutions with cytoprotective agents and perfusion may improve pancreas and islet transplant outcomes.

Keywords
islet isolation, islet transplants, pancreas preservation, pancreas procurement, pancreas transplants

Introduction

Pancreas and islet transplants are two options for patients who, because of serious diabetic conditions, will benefit from β-cell replacement. The numbers of clinical pancreas transplants have increased exponentially and outcomes have improved markedly, especially during the past two decades [1]. The improvements in outcomes are attributed to better recipient care with respect to surgical techniques and immunosuppressive regimens and to better organ procurement and preservation protocols. In this review, we summarize the recent literature regarding the current state-of-the-art in pancreas procurement and preservation. Our focus is on pancreas preservation before islet isolation, which appears to have more stringent requirements than pancreas preservation for whole-pancreas transplants, due to the added stresses

experienced by the islets during the isolation and purification process. In addition, we provide a brief review of current advances in islet protection and preservation during isolation and culture.

Pancreas procurement

There are several well established techniques for multi-organ procurement. The two main techniques for pancreas are en-bloc procurement, and in-vivo dissection [2].

In a recent report, Brockmann et al. [3*] performed a meta-analysis of the literature on organ procurement for transplants and favored rapid en-bloc removal of the abdominal organs with separation on the back table. Dalle Valle et al. [2] reported that pancreas grafts procured by in-vivo dissection and in-situ separation

maintained excellent quality. Dalle Valle noted that successful in-vivo dissection was influenced by the experience and ability of the operating surgeons, more so than when the back-table technique was used, suggesting that the back-table technique might be preferred in the absence of a dedicated team of experienced surgeons.

The techniques described above are most likely sufficient for organ procurement from brain-dead donors, but they may be inadequate for procurement of organs from donors after cardiac death. The increasing demand for, and limited availability of, organs for transplants have prompted the use of pancreases procured from donors after cardiac death [4]. Such pancreases have also recently been successfully processed for islets and used for clinical islet transplants in Japan [5,6**,7,8*]. The in-situ regional organ cooling system originally developed for kidney procurement [9] was modified for pancreas procurement [8*]. After confirmation of brain death, a double-balloon catheter is inserted into the aorta through the femoral artery; the tip of the double-balloon catheter is placed above the level of the celiac axis [9]. Ultrasound is used to confirm balloon placement. In order to prevent warm ischemic damage, regional in-situ cooling of the pancreas and kidney is achieved by infusion of a hypothermic preservation solution. The flush is initiated immediately after the donor's cardiac arrest and continued until organ procurement is complete. A venous catheter is also placed in the inferior vena cava via the femoral vein to vent the perfusate.

Pancreas preservation for pancreas transplantation

The two main methods used for experimental and clinical organ preservation are static cold storage, which we will simply refer to as cold storage, and machine perfusion [10–20,21*,22*,23–34,35*,36,37*,38–44]. The hypothermic pulsatile machine perfusion technique originally developed by Carrel and Lindbergh in 1935 [45–47] has been widely used for clinical kidney transplants [48] but not for clinical pancreas preservation.

Early experiments with canine segmental pancreas grafts, reported by Florack et al. [16], demonstrated that failure rates with machine perfusion were 30% at 24 h and 40% at 48 h. There were no failures at 24 and 48 h with cold storage. These results, along with the complexities associated with machine perfusion of the pancreas, have made cold storage the preferred and most widely used method for pancreas preservation [44].

Pancreases preserved with cold storage and transplanted immediately as vascularized grafts nearly always restore insulin independence in the recipient. When pancreases are preserved for islet transplantation, two to three donor pancreases may be required per recipient to achieve insulin independence [49], in some but not all centers [50].

The need for more than one donor pancreas per recipient for islet transplants may be attributed to at least three problems: first, to the lower quality of pancreases selected and offered for islet transplants compared with those organs offered for whole-pancreas transplantation; second, to exposure of islets to a series of damaging physicochemical stresses during isolation that may amplify the damage caused during cold storage; and third, to the further damage of islets during purification and culture [38].

University of Wisconsin solution (UWS) has been the standard preservation solution for pancreas transplantation for almost 20 years [36]. Recently, multiple reports have suggested that other preservation solutions may be effective alternatives to UWS [18–20,22*].

In 2006, Englesbe et al. [21*] reported the results of a multicenter study using histidine-tryptophan-ketoglutarate (HTK). The study population consisted of 77 consecutive pancreas recipients: 41 were in the UWS group and 36 were in the HTK group. Pancreas graft function, at 90 days posttransplant, the technical graft loss rates, and the pancreatic leak rates were similar between the groups, with no significant differences in postoperative amylase and lipase levels. Similarly, in 2007, Becker et al. [22*] reported no significant differences in patient survival or graft survival between UWS ($n = 47$) and HTK ($n = 48$) groups. Furthermore, peak lipase on postoperative day 1, serum amylase and C-reactive protein were not significantly different between the two groups. Some reports, including the one by Becker et al. [22*], have indicated that HTK-flushed pancreata appeared more edematous [18–20,21*,22*]. However, this edema did not appear to impair early graft function [22*].

Celsior, an extracellular, low-viscosity preservation solution originally designed for heart transplantation has also been used for experimental pancreas [23–25] and other organ preservation [26–32]. For whole-pancreas transplantation, the use of Celsior has been controversial [23–25]. Baldan et al. [24] demonstrated that Celsior was an effective alternative to UWS for pancreas procurement in a pig autotransplant model, whereas Uhlmann et al. [25] reported, using the same model, that the use of Celsior was associated with increased ischemia-reperfusion injury, when compared with UWS. Recently, in a pig allotransplant model, Garcia-Gil et al. [33] demonstrated that lipid peroxidation after reperfusion of pancreases preserved in Celsior and UWS was similar.

The first prospective, randomized study comparing UWS ($n = 50$) with Celsior ($n = 50$) for clinical pancreas

transplants was recently reported by Boggi *et al.* [34]. The authors demonstrated that Celsior and UWS had similar safety profiles for pancreas preservation. Another study reported by Manrique *et al.* [35*] comparing Celsior (*n* = 28) with UWS (*n* = 44) for pancreas preservation demonstrated that 2-year recipient survival rates, 2-year graft survival rates, pancreas leakage rates, and clinical graft pancreatitis rates were similar in both groups.

Pancreas preservation for Islet transplantation

UWS has been used since the 1980s as the pancreas preservation solution [36] for clinical islet transplants. Salehi *et al.* [37*] recently reported that islet yields from human pancreases preserved in HTK or UWS were equivalent. A recent study by Hubert *et al.* [51*], demonstrated that the islet isolation yields, as measured in islet equivalents per gram pancreas, from pancreases preserved with Celsior solution were 2.1-fold lower than those obtained when UWS was used ($P < 0.05$). Based on these results, Hubert *et al.* [51*] suggested that colloid-free preservation solutions might be suboptimal for pancreas perfusion and cold storage prior to islet isolation and transplantation [38].

Two French groups recently demonstrated the possibility of clinical application of solution de conservation d'organes et de tissus (SCOT), which has been shown to have some immunoprotective effects on islet cells. SCOT, an extracellular solution containing polyethylene glycol (PEG), is an oncotic agent, which may induce immunocamouflage of the graft's surface antigens [52]. In addition, Hubert *et al.* [51*] demonstrated that cell swelling and pancreas edema were not significant following 12 h of cold storage with SCOT, compared with UWS – a finding that may be related to the presence of PEG. Giraud *et al.* [53] demonstrated that SCOT could improve islet yield when used during isolation and could prolong islet allograft survival without immunosuppression when used for culture, as compared with control solutions.

There is consensus among the major islet transplantation centers that islet yields and quality can be improved with better pancreas procurement techniques and by the use of cold-preservation techniques that are not necessarily needed for whole-pancreas transplants. The two-layer method (TLM) for pancreas preservation is an example of a coordinated effort to improve islet yield and quality by improving pancreas oxygenation during preservation. In 2002, the University of Minnesota [38], University of Miami [39], and University of Alberta [40,41] reported that the TLM improved islet yield and increased islet transplant opportunities. Since then, the TLM has been widely used by islet transplant centers worldwide.

The mechanisms by which the TLM improves human islet yield and quality are not fully understood. A standard explanation is the improved oxygenation of the pancreas during cold storage with the TLM. It has been suggested that during islet isolation and transplantation, apoptosis is initiated and executed mainly through the mitochondrial and mitogen-activated protein kinase (MAPK) pathways [54–56]. Matsuda *et al.*, using a rat model [57], and Ramachandra *et al.*, using human pancreases [58**], demonstrated improved islet yield from pancreata preserved with the TLM. These results may be attributed to inhibition of apoptosis mediated by the mitochondrial pathway.

Noguchi *et al.* [59*], using a pig model, reported that the islet yield from pancreases preserved with the TLM using a modified ET-Kyoto solution (Otsuka Pharmaceutical Factory, Inc., Tokyo, Japan) was significantly higher when compared with the TLM using UWS. Interestingly, Noguchi *et al.* found no significant difference in islet viability, in-vitro or in-vivo function between the two preservation methods [59*]. They also recently demonstrated improvements in islet isolation using M-Kyoto solution [60*] instead of UWS [61] for ductal injection. They hypothesized that M-Kyoto solution is less likely to inhibit collagenase activity than UWS [62].

Brandhorst *et al.* [63], demonstrated that a simpler preservation method, the one-layer method (OLM), using oxygenated perfluorocarbon, could be used as an alternative to the TLM. They suggested that short-term storage in oxygenated perfluorocarbon improved the in-vitro but not the in-vivo function of pig islets that were damaged by warm ischemia. Three hours of additional pancreas 'oxygenation' with the OLM significantly increased ATP content in pig islets exposed to 30 min of warm ischemia, resulting in recovery of in-vitro function but not in significant improvements in posttransplant function [64*]. These observations are quite interesting as the perfluorocarbon does not contain any substrate for ATP regeneration, does not contain any additives with antioxidant properties, and does not include any of the compounds that are expected to prevent cellular edema during cold storage.

In contrast to observations by Brandhorst *et al.* in the porcine model, Kuroda's group [65], using a rat transplant model, demonstrated that pancreata damaged by 30 min of warm ischemia were restored after 3 h of TLM preservation [63]. These discrepancies may be explained by species-dependent differences in pancreas size and texture [66*]. Porcine and human pancreata are much thicker, and are often covered by significant amounts of fat, as compared with canine pancreases. Papas *et al.* [67], using a porcine model, demonstrated that only 15% of the total pancreatic volume was oxygenated during TLM

preservation with oxygen-saturated perfluorocarbon, suggesting the need for substantial improvement in pancreas oxygenation and preservation, even when the TLM is used.

In a recent large-scale clinical study, the Edmonton group [68*] demonstrated no beneficial effect of the TLM with preoxygenated perfluorocarbon on islet isolation and islet transplant outcomes ($n = 75$). In addition, the Uppsala group [69**] recently reported results from 200 islet isolations, and found that the TLM did not improve islet isolation or clinical outcome posttransplant.

The 2007 Annual Report of the Collaborative Islet Transplant Registry (CITR) [70] provided information on islet characteristics with regard to pancreases preserved by the TLM or UWS. The data were collected from the 31 active islet transplant programs in North America from 1999 to 2006. According to the data, islet yields did not significantly differ between pancreata preserved with the TLM ($366,467 \pm 11,418$, $n = 161$) or UWS ($390,532 \pm 7,440$, $n = 330$). Additional information on islet viability did not reveal any substantial differences between the two groups. The membrane integrity tests, however, utilized for generating the reported viability data are known to be insensitive [71]. In addition, the retrospective analysis reported by the CITR did not indicate the exact methods of perfluorocarbon oxygenation in the TLM, (saturated compared with continuous oxygen supply), the duration of cold ischemia in the two groups, or any relationship or overlap between the pancreas procurement teams and the processing and infusion teams.

The different perfluorocarbon oxygenation methods (presaturated without replenishment compared with continuous oxygen supply) are unlikely to explain the controversial findings on the benefits of the TLM in pancreas preservation. Even in the best-case scenario for oxygenation (perfluorocarbon continuously bubbled and fully saturated with oxygen), the oxygen penetration depth cannot be expected to exceed 1 mm, leaving a large portion of human and porcine pancreata oxygen-limited [66*,67].

It is hypothesized that more sophisticated preservation protocols may be necessary and should replace cold storage, with or without TLM, in order to improve islet yields and quality. This is supported by recent data [73*] indicating that machine perfusion of porcine pancreases for 24 h improved isolation yields by approximately three-fold compared with cold storage and by approximately two-fold compared with fresh procurement. The mechanisms behind these improvements are unclear; it has been suggested that edema caused by perfusion may facilitate more efficient islet isolation [73*]. In addition, intermittent capillary perfusion at low flow rates may facilitate pancreas preservation by maintaining better

functional capillary density, compared with cold storage [74]. Capillary perfusion may be important for pancreas transplants, but may be less of an issue for islet transplants.

The implementation of recently developed tools for pancreas and islet quality assessment [71,72*] is expected to contribute to more thorough and sensitive evaluation of existing, as well as much-needed new, pancreas preservation strategies, and perhaps help answer some of the long-standing questions in the field.

Islet protection and preservation

Goto et al. recently exploited the ability of perfluorocarbon to store high amounts of oxygen to better oxygenate islets during the isolation process [75*]. They demonstrated that the use of oxygenated perfluorocarbon during islet isolation resulted in improved islet yield and quality, which suggests that hypoxia during islet digestion may damage islets [75*].

Ichii et al. [76**] demonstrated that the addition of nicotinamide to the processing medium significantly improved islet yield and increased the success rate of isolation. Nicotinamide, a cytoprotective compound, may ameliorate injuries caused by oxidative stresses and various cytokines. In addition, nicotinamide supplementation of the processing medium reduced the islet production of tissue factor, which may trigger thrombotic reactions after portal islet infusion. Nicotinamide also reduced the islet production of macrophage chemoattractant protein (MCP-1), which has a potent chemotactic activity for monocytes. Korsgren's group [77] demonstrated that nicotinamide supplementation of culture medium was effective in reducing both tissue factor and MCP-1 production by islets, which led to the inhibition of the instant blood-mediated inflammatory reaction when islets came into contact with blood.

Islet isolation activates the c-Jun NH2-terminal kinase (JNK), a member of the stress-activated group of MAPKs [55,56]. Noguchi et al. investigated the efficacy of a JNK inhibitory peptide (JNKI) to inhibit cell apoptosis in islets isolated from pancreata preserved with the TLM [78,79]. They demonstrated that JNKI prevented islet cell apoptosis induced immediately after isolation and that JNKI improved islet yield and islet graft function after 1 day of culture [78,79]. Similar findings were recently reported by Ito et al. using an inhibitor of p38 MAPK during islet preservation [80].

Conclusion

The management of donor pancreas preservation affects clinical outcomes in pancreas, and especially islet,

transplant recipients. In-situ regional organ cooling may protect the pancreas from warm ischemic injury when managing donors after cardiac death. Colloid-free preservation solutions such as Celsior and HTK, have been demonstrated to perform comparably to UWS when used for pancreas preservation for subsequent pancreas transplants. Colloid-free preservation solutions were reported to be inferior to UWS for preservation of pancreases intended to be used for islet isolation. Pancreas preservation for islet isolation and transplants may have different requirements: cold storage with or without the TLM may be insufficient. Recent studies with large numbers of pancreases did not demonstrate significant differences in islet yields and in clinical islet allotransplant outcomes with pancreases stored with TLM when compared with cold storage. Pancreas size and texture variations and methods of perfluorocarbon oxygenation may influence the oxygenated volume fraction and the quality of the preserved pancreas. Agents that block stress-signaling pathways and that may interfere with apoptosis, such as JNK and p38 inhibitors, may improve islet yield and quality. Nicotinamide supplementation of the medium has also been reported to be effective for preserving islets. The lack of real-time, quantitative objective tools for assessing the quality of pancreases during and after cold storage and the quality of islets after isolation has hindered progress. The recent development and implementation of such tools [71,72*] is expected to contribute significantly, in the near future, to needed advances in preservation of pancreases to be used for islet isolation and transplantation.

Acknowledgements

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest

1   Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005; 19:433–455.

2   Dalle Valle R, Capocasale E, Mazzoni MP, et al. Pancreas procurement technique. Lessons learned from an initial experience. Acta Biomed 2006; 77:152–156.

3   Brockman JG, Vaidya A, Reddy S, Friend PJ. Retrieval of abdominal organs for
•   transplantation. Br J Surg 2006; 93:133–146.
In this article, the literature on organ procurement is analyzed with the intention of providing an evidence-based protocol for the management of multiorgan donors.

4   Markmann JF, Deng S, Desai NM, et al. The use of nonheart-beating donors for isolated pancreatic islet transplantation. Transplantation 2003; 78:1423–1429.

5   Onaca N, Naziruddin B, Matsumoto S, et al. Pancreatic islet cell transplantation: Update and new developments. Nutr Clin Pract 2007; 22:485–493.

6   Matsumoto S, Okitsu T, Iwanaga Y, et al. Successful islet transplantation from
•• nonheartbeating donor pancreata using modified Ricordi islet isolation method. Transplantation 2006; 82:460–465.
This article demonstrates the use of expanded donors for islet transplantation in Japan.

7   Noguchi H, Iwanaga Y, Okitsu T, et al. Evaluation of islet transplantation from nonheart beating donors. Am J Transplant 2006; 6:2476–2482.

8   Nagata H, Matsumoto S, Okitsu T, et al. Procurement of the human pancreas
•   for pancreatic islet transplantation from marginal cadaver donors. Transplantation 2006; 82:327–331.
This article describes a technique for pancreas procurement from donors after cardiac death.

9   Tojimbara T, Fuchinoue S, Iwadoh K, et al. Improved outcomes of renal transplantation from cardiac death donors: a 30-year single center experience. Am J Transplant 2007; 7:609–617.

10 Troisi R, Meester D, Regaert B, et al. Physiologic and metabolic results of pancreatic cold storage with Histidine-Tryptophan-Ketoglutarate-HTK solution (Custodiol) in the porcine autotransplantation model. Transpl Int 2000; 13:98–105.

11 Bretschneider HJ. Myocardial protection. Thorac Cardiovasc Surg 1980; 28:295–302.

12 Erhard J, Lange R, Scherer R, et al. Comparison of histidine-tryptophan-ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantation. A prospective, randomized study. Transpl Int 1994; 7:177–181.

13 Baumgartner D, Sutherland DE, Najarian JS. Studies on segmental pancreas autotransplants in dogs: technique and preservation. Transplant Proc 1980; 12 (4 Suppl 2):163–171.

14 Brynger H. Twenty-four-hour preservation of the duct-ligated canine pancreatic allograft. Eur Surg Res 1975; 7:341–354.

15 Toledo-Pereyra LH, Valjee KD, Chee M, et al. Preservation of the pancreas for transplantation. Surg Gynecol Obstet 1979; 148:57–61.

16 Florack G, Sutherland DE, Heil J, et al. Preservation of canine segmental pancreatic autografts: cold storage versus pulsatile machine perfusion. J Surg Res 1983; 34:493–504.

17 Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation 1988; 45:673–676.

18 Potdar S, Malek S, Eghtesad B, et al. Initial experience using histidine-tryptophan-ketoglutarate solution in clinical pancreas transplantation. Clin Transplant 2004; 18:661–665.

19 Fridell JA, Agarwal A, Milgrom ML, et al. Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution for organ preservation in clinical pancreas transplantation. Transplantation 2004; 77: 1304–1306.

20 Agarwal A, Murdock P, Pescovitz MD, et al. Follow-up experience using histidine-tryptophan-ketoglutarate solution in clinical pancreas transplantation. Transplant Proc 2005; 37:3523–3526.

21 Englesbe MJ, Moyer A, Kim DY, et al. Early pancreas transplant outcomes with
•   histidine-tryptophan-ketoglutarate preservation: a multicenter study. Transplantation 2006; 82:136–139.
This article reports on a multicenter study describing the clinical experience with HTK solution in pancreas transplantation.

22 Becker T, Ringe B, Nyibata M, et al. Pancreas transplantation with histidine-
•   tryptophan-ketoglutarate (HTK) solution and University of Wisconsin (UW) solution: is there a difference? JOP 2007; 8:304–311.
This article reports that HTK solution is clinically comparable to UWS in pancreas transplantation.

23 Baldan N, Parise P, Furian L, et al. Swine pancreas preservation with Celsior solution. Transplant Proc 2000; 32:29–31.

24 Baldan N, Rigotti P, Furian L, et al. Pancreas preservation with Celsior solution in a pig autotransplantation model: comparative study with University of Wisconsin solution. Transplant Proc 2001; 33:873–875.

25 Uhlmann D, Armann B, Ludwig S, et al. Comparison of Celsior and UW solution in experimental pancreas preservation. J Surg Res 2002; 105:173–180.

26 Thabut G, Vinatier I, Brugiere O, et al. Influence of preservation solution on early graft failure in clinical lung transplantation. Am J Crit Care Med 2001; 164:1204–1208.

27 Maggi U, Caccamo L, Gatti S, et al. Celsior solution and clinical liver transplantation. Transplant Proc 2000; 32:36–37.

28 Meneu Diaz JC, Vicente E, Nuno J, et al. Prospective comparative study of the efficacy of Celsior solution for preservation in clinical liver transplant. Transplant Proc 2002; 34:49.

29 Lama C, Rafecas A, Figueras J, et al. Comparative study of Celsior and Belzer solutions for hepatic graft preservation: preliminary results. Transplant Proc 2002; 34:54–55.

30 Nardo B, Catena F, Cavallari G, et al. Randomized clinical study comparing UW and Celsior solution in liver preservation for transplantation: preliminary results. Transplant Proc 2001; 33:870–872.

31 Cavallari A, Cillo U, Nardo B, et al. A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. Liver Transpl 2003; 9:814–821.

32 Faenza A, Catena F, Nardo B, et al. Kidney preservation with University of Wisconsin and Celsior solution: a prospective multicenter randomized study. Transplantation 2001; 72:1274–1277.

33 Garcia-Gil FA, Gonzalvo E, Garcia-Garcia JJ, et al. Lipid peroxidation in ischemia-reperfusion oxidative injury of the graft preserved in Celsior and University of Wisconsin solutions on a pig pancreas transplantation model. Transplant Proc 2006; 38:2595–2599.

34 Boggi U, Vistoli F, Del Chiaro M, et al. Pancreas preservation with University of Wisconsin and Celsior solutions: a single-center, prospective, randomized pilot study. Transplantation 2004; 77:1186–1190.

35 Manrique A, Jimenez C, Herrero ML, et al. Pancreas preservation with the
• University of Wisconsin versus Celsior solutions. Transplant Proc 2006; 38:2582–2584.
This article reports that Celsior solution is comparable with UWS for pancreas preservation.

36 Zuker PF, Bloom AD, Strasser S, Alejandro R. Successful cold storage preservation of canine pancreas with UW-1 solution prior to islet isolation. Transplantation 1989; 48:168–170.

37 Salehi P, Hansen MA, Avila JG, et al. Human islet isolation outcomes from
• pancreata preserved with Histidine-Tryptophan Ketoglutarate versus University of Wisconsin solution. Transplantation 2006; 82:983–985.
This article reports that HTK solution is equivalent to UWS for pancreas preservation for islet transplantation.

38 Hering BJ, Matsumoto I, Sawada T, et al. Impact of two-layer pancreas preservation on islet isolation and transplantation. Transplantation 2002; 74:1813–1816.

39 Fraker CA, Alejandro R, Ricordi C. Use of oxygenated perfluorocarbon toward making every pancreas count. Transplantation 2002; 74:1811–1812.

40 Tsujimura T, Kuroda Y, Kin T, et al. Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) cold-storage method. Transplantation 2002; 74:1687–1691.

41 Lakey JR, Tsujimura T, Shapiro AM, Kuroda Y. Preservation of the human pancreas before islet isolation using a two-layer (UW solution-perfluorochemical) cold storage method. Transplantation 2002; 74:1809–1811.

42 Matsumoto S, Rigley TH, Qualley SA, et al. Efficacy of the oxygen-charged static two-layer method for short-term pancreas preservation and islet isolation from nonhuman primate and human pancreata. Cell Transplant 2002; 11:769–777.

43 Iwanaga Y, Suzuki Y, Okada Y, et al. Ultrastructural analyses of pancreatic grafts preserved by the two-layer cold-storage method and by simple cold storage in University of Wisconsin solution. Transpl Int 2002; 15:425–430.

44 Maathuis MH, Leuvenink HG, Ploeg RJ. Perspectives in organ preservation. Transplantation 2007; 83:1289–1298.

45 Carrel A, Lindbergh CA. The culture of organs. New York: Hoeber; 1938.

46 Malinin TI. Remembering Alexis Carrel and Charles A. Lindbergh. Tex Heart Inst J 1996; 23:28–35.

47 Bing RJ. Lindbergh and the biological sciences (a personal reminiscence). Tex Heart Inst J 1987; 14:230–237.

48 Belzer FO, Ashby BS, Dunphy JE. 24-h and 72-h preservation of canine kidneys. Lancet 1967; 2:536–538.

49 Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355:1318–1330.

50 Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293:830–835.

51 Hubert T, Gmyr V, Arnalsteen L, et al. Influence of preservation solution on
• human islet isolation outcome. Transplantation 2007; 83:270–276.
This study suggests that colloid-free preservation solutions might be suboptimal for pancreas perfusion and cold storage prior to islet isolation and transplantation.

52 Scott MD, Chen AM. Beyond the red cell: pegylation of other blood cells and tissues. Transfus Clin Biol 2004; 11:40–46.

53 Giraud S, Claire B, Eugene M, et al. A new preservation solution increased islet yield and reduces graft immunogenicity in pancreatic islet transplantation. Transplantation 2007; 83:1397–1400.

54 Thomas F, Wu J, Contreras JL, et al. A tripartite anoikis-like mechanism causes early isolated islet apoptosis. Surgery 2001; 130:333–338.

55 Paraskevas S, Aikin R, Maysinger D, et al. Activation and expression of ERK, JNK, and p38 MAP-kinases in isolated islets of Langerhans: implications for cultured islet survival. FEBS Lett 1999; 455:203–208.

56 Paraskevas S, Aikin R, Maysinger D, et al. Modulation of JNK and p38 stress activated protein kinases in isolated islets of Langerhans: insulin as an autocrine survival signal. Ann Surg 2001; 233:124–133.

57 Matsuda T, Suzuki Y, Tanioka Y, et al. Pancreas preservation by the 2-layer cold storage method before islet isolation protects isolated islets against apoptosis through the mitochondrial pathway. Surgery 2003; 134:437–445.

58 Ramachandran S, Desai NM, Goers TA, et al. Improved islet yields
•• from pancreas preserved in perflurocarbon is via inhibition of apoptosis mediated by mitochondrial pathway. Am J Transplant 2006; 6:1696–1703.
This study attempts to explain the mechanism by which TLM may improve islet yields. It suggests that TLM improvements are via the inhibition of apoptosis mediated by the mitochondrial pathway. Of note is that the comparisons were conducted between oxygen saturated perfluorocarbon in TLM and air saturated UWS. Perhaps an additional comparison of interest would be between oxygen saturated perfluorocarbon in TLM and oxygen saturated UWS.

59 Noguchi H, Ueda M, Nakai Y, et al. Modified two-layer preservation method
• (M-Kyoto/PFC) improves islet yields in islet isolation. Am J Transplant 2006; 6:496–504.
This article suggests that TLM using M-Kyoto Solution significantly improves islet yields compared with TLM using University of Wisconsin solution.

60 Noguchi H, Ueda M, Hayashi S, et al. Comparison of M-Kyoto solution
• and histidine-tryptophan-ketoglutarate solution with a trypsin inhibitor for pancreas preservation in islet transplantation. Transplantation 2007; 84: 655–658.
This study suggests that for pancreas preservation for islet isolation and transplantation, M-Kyoto solution may be better than HTK when used in conjunction with TLM.

61 Sawada T, Matsumoto I, Nakano M, et al. Improved islet yield and function with ductal injection of University of Wisconsin solution before pancreas preservation. Transplantation 2003; 75:1965–1969.

62 Contractor HH, Johnson PR, Chadwick DR, et al. The effect of UW solution and its components on the collagenase digestion of human and porcine pancreas. Cell Transplant 1995; 4:615–619.

63 Brandhorst D, Iken M, Bretzel RG, et al. Successful pancreas preservation by a perfluorocarbon-based one-layer method for subsequent pig islet isolation. Transplantation 2005; 79:433–437.

64 Brandhorst D, Iken M, Bretzel RG, Brandhorst H. Pancreas storage in
• oxygenated perfluorodecalin does not restore posttransplant function of isolated pig islets predamaged by warm ischemia. Xenotransplantation 2006; 13:465–470.
This study reports that short-term storage of pancreases in preoxygenated perfluorodecalin improves the in-vitro but not the in-vivo function of ischemically-damaged islets.

65 Tanaka T, Suzuki Y, Tanioka Y, et al. Possibility of islet transplantation from a nonheartbeating donor pancreas resuscitated by the two-layer method. Transplantation 2005; 80:738–742.

66 Avgoustiniatos ES, Hering BJ, Papas KK. The rat pancreas is not an appro-
• priate model for testing the preservation of the human pancreas with the two-layer method. Transplantation 2006; 81:1471–1472.
This report alerts the community to issues related to the effect of pancreas size on pancreas oxygenation by diffusion during cold storage and notes that results obtained with pancreases from small animals (rodents) are not directly translatable to thicker porcine and human pancreases.

67 Papas KK, Hering BJ, Guenther L, et al. Pancreas oxygenation is limited during preservation with the two-layer method. Transplant Proc 2005; 37:3501–3504.

68 Kin T, Mirbolooki M, Salehi P, et al. Islet isolation and transplantation outcomes
• of pancreas preserved with University of Wisconsin solution versus two-layer method using preoxygenated perfluorocarbon. Transplantation 2006; 82: 1286–1290.
This article demonstrates that there is no beneficial effect of TLM with preoxygenated PFC on islet isolation and transplantation outcomes based on a large-scale clinical study.

69 Caballero-Corbalan J, Eich T, Lundgren T, *et al.* No beneficial effect of two-
•• layer storage compared with UW-storage on human islet isolation and
transplantation. Transplantation 2007; 84:864–869.
This report suggests that there is no beneficial effect of TLM with preoxygenated
perfluorocarbon on islet isolation and transplantation outcomes based on results
with 200 human pancreases.

70 Collaborative Islet Transplant Registry (CITR) Annual Report. Rockville, MD:
The EMMES Corporation; Aug 2007.

71 Papas KK, Colton CK, Nelson RA, *et al.* Human islet oxygen consumption rate
and DNA measurements predict diabetes reversal in nude mice. Am J
Transplant 2007; 7:707–713.

72 Scott W, Matsumoto S, Tanaka T, *et al.* Real-time noninvasive assessment of
• pancreatic ATP levels during preservation. Transplantation proceedings
2008; 40:403–406.
This study reports on the effectiveness of SCOT solution in reducing islet
immunogenicity when used in islet isolation and culture.

73 Taylor MJ, Baicu S, Leman B, *et al.* Twenty-four hour hypothermic machine
• perfusion preservation of porcine pancreas facilitates processing for islet
isolation. Transplantation proceedings 2008; 40:480–482.
This study suggests that machine perfusion may facilitate islet processing and
improve islet yields when compared with fresh as well as cold-stored porcine
pancreases, even after 24 h of preservation.

74 Preissler G, Massberg S, Waldner H, Messmer K. Intermittent capillary
perfusion in rat pancreas grafts following short- and long-term preser-
vation in University of Wisconsin solution. Transpl Int 2006; 19:325–332.

75 Goto T, Tanioka Y, Sakai T, *et al.* Application of the two-layer method on
• pancreas digestion results in improved islet yield and maintained viability of
isolated islets. Transplantation 2007; 83:754–758.
This study suggests that improvement of oxygenation by the addition of perfluor-
ocarbon during islet digestion may have a beneficial effect on islet yield. This study
suggests that hypoxia during islet processing may be negatively affecting islet
isolation outcomes and that ways to improve oxygenation may be necessary to
further improve islet yield and isolated islet quality.

76 Ichii H, Wang X, Messinger S, *et al.* Improved human islet isolation using
•• nicotinamide. Am J Transplant 2006; 6:2060–2068.
This study reports that nicotinamide supplementation of the processing medium
reduces the production of tissue tactor and macrophage chemoattractant protein
from islet preparations.

77 Moberg L, Olsson A, Berne C, *et al.* Nicotinamide inhibits tissue factor
expression in isolated human pancreatic islets: implications for clinical islet
transplantation. Transplantation 2003; 76:1285–1288.

78 Noguchi H, Nakai Y, Matsumoto S, *et al.* Cell permeable peptide of JNK
inhibitor prevents islet apoptosis immediately after isolation and improves islet
graft function. Am J Transplant 2005; 5:1848–1855.

79 Noguchi H, Matsumoto S, Kobayashi N, *et al.* Pancreas preservation with JNK
inhibitor protects isolated islets against apoptosis and improves islet graft
function. Xenotransplantation 2007; 14:480–481.

80 Ito T, Omori K, Rawson J, *et al.* Increased islet yield by p38 mitogen-activated
protein kinase (MAPD) inhibitor infusion of the canine pancreas prior to
overnight cold preservation. Xenotransplantation 2007; 14:388.

6 糖尿病に対する外科的治療法

—膵臓移植と膵島移植—

岩永康裕，上本伸二

京都大学医学部附属病院臓器移植医療部

●*Key Words* ● 膵臓移植，膵島移植，インスリン離脱

Summary . . . .

●膵臓移植は全身麻酔下の手術が必要で侵襲度は大きいが，1 度の移植で高いインスリン離脱率を維持可能である．膵島移植はインスリン離脱に複数回の移植が必要で，インスリン離脱したとしてもそれを長期間維持するのは難しい．しかし，高い安全性と血糖値の不安定性に対する治療効果は確認されている．

●膵臓移植と膵島移植の選択については，両者のメリット・デメリットおよび患者の病期を考慮して選択されるべきである．また，医学的に耐術性がない，あるいは膵臓移植の適応から外れる症例でも，膵島移植なら適応となる場合がある．

はじめに

　膵臓移植と膵島移植はどちらも 1 型糖尿病等のインスリン依存状態糖尿病に対する外科的治療法で，膵 β 細胞を補充し適正なインスリン分泌を再開することによって糖代謝を正常化させることを目的としている．糖代謝の正常化により血糖値は安定化し quality of life（QOL）は劇的に向上する．また，糖尿病性合併症の発症・進展を予防することにもなる．膵臓移植は臓器移植であるのに対して，膵島移植は膵臓から膵島（＝ランゲルハンス島，ラ氏島）のみを分離して移植する細胞（組織）移植である．

　本稿では，膵臓移植と膵島移植の現況と，それらの選択について述べる．

膵臓移植

　膵臓移植は 1966 年米国ミネソタ大学において世界で初めて行われた．1 度の移植で高いインスリン離脱率を維持可能で，特に膵腎同時移植では QOL の改善のみでなく救命・延命効果も認められ，糖尿病性腎不全に対する根治療法として定着している．

膵臓移植の分類

　膵臓移植は，ドナーによって，①脳死ドナー膵臓移植，②心停止ドナー膵臓移植，③生体ドナー膵臓移植に分類できる．大多数が脳死ドナー膵臓移植であるが，心停止ドナー膵臓移植も少数の報告例がある．生体ドナー膵臓移植は健常なドナーの膵体尾部を用いるものであるが，死

体ドナー数が極端に少ない日本では最近その数が増えてきている.

次に術式によって，①膵腎同時移植（Simultaneous Pancreas Kidney Transplant：SPK），②腎移植後膵移植（Pancreas Transplant after Kidney：PAK），③膵単独移植（Pancreas Transplant Alone：PTA）に分類できる．膵腎同時移植（SPK）は糖尿病性腎不全患者に対して膵臓と腎臓を同時に移植するものである．腎移植後膵移植（PAK）は糖尿病性腎不全で予め腎移植を受けた患者に対して膵臓移植を追加するものである．膵単独移植（PTA）は非腎不全糖尿病患者に対して膵臓のみを単独で移植するものである.

膵液のドレナージ法には膀胱ドレナージ法（Bladder Drainage：BD）と腸管ドレナージ法（Enteric Drainage：ED）がある．膀胱ドレナージ法（BD）は膵頭部に付いている十二指腸をレシピエントの膀胱に吻合して膵液を膀胱内に誘導する方法で，尿中のアミラーゼ値をモニターリングすることで，拒絶反応の補助診断が可能という長所がある．しかし，感染などの尿路系合併症が多くなる．一方,腸管ドレナージ法（ED）は，十二指腸をレシピエントの小腸に吻合して膵液を腸管内に誘導する生理的な方法である．近年，免疫抑制法が進歩したこと，またBD施行後に尿路系合併症によるEDへの変更手術（enteric conversion）が必要となる症例がしばしばあることから，EDが多くなっている.

静脈血の還流法には，グラフトの静脈をレシピエントの腸骨静脈に吻合する大循環系ドレナージ法（Systemic Drainage）と上腸間膜静脈に吻合して門脈系に還流させる門脈系ドレナージ法（Portal Drainage）がある.

膵臓移植後合併症

移植後早期の合併症として，移植した膵臓の静脈（門脈）または動脈内に血栓ができる場合があり，移植膵臓の摘出が必要となることがある．他に移植膵膵炎，感染がある．感染が進んで移植膵臓の摘出が必要になる場合もある．レシピエントが死に至るといった重篤なものもある.

BDにおいては膵液がそのまま尿として排泄されるので，脱水や膵液中の重炭酸の喪失による代謝性アシドーシスを来す．高度な場合は，Enteric Conversionが必要なことがある．また，尿路感染と排尿障害が起こることがある.

世界の膵臓移植の現況

国際膵臓移植登録（International Pancreas Transplant Registry：IPTR）によると最近では世界で年間1,700件前後実施され，2006年12月の時点で累積症例数は26,000例を越している．膵臓移植のカテゴリー別の成績（2000年1月から2004年6月）は，患者1年生存率はSPK 95%，PAK 95%，PTA 98%，グラフト1年生着（インスリン離脱）率はSPK 85%，PAK 78%，PTA 76%である．5年生着（インスリン離脱）率はそれぞれSPK 69%，PAK 58%，PTA 58%である[1]．各術式数をみると，SPKが71%，PAKが21%，PTAが8%を占めていて，多くの場合SPKが行われている.

日本の膵臓移植の現況

日本では，臓器移植法施行前に1984〜1994年までに15例の膵臓移植が行われた．1997年

の臓器移植法施行以降は 2007 年 12 月末までに 58 例が行われた．内訳は脳死ドナー移植 42 例，心停止ドナー移植 2 例，生体ドナー移植 14 例である．カテゴリー別でみると，SPK46 例，PAK6 例，PTA6 例である．日本の膵臓移植はコンディションが良くないドナー（marginal donor）の膵臓を使用することが多いにもかかわらず，欧米と遜色ない移植成績である．

　2006 年 4 月 1 日より脳死および心停止ドナーを用いた膵臓移植は保険適応となっている．

膵島移植

　膵島移植は，膵島（ランゲルハンス島）を膵臓から分離し，レシピエントに移植する細胞（組織）移植である．大がかりな手術を必要とせず，通常は局所麻酔によって経皮経肝的に門脈内に留置したカテーテルから膵島を注入することによって肝臓内に移植する．

膵島移植の分類

　膵島移植もドナーによって，①脳死ドナー膵島移植，②心停止ドナー膵島移植，③生体ドナー膵島移植に分類できる．海外では脳死ドナーを用いているが，日本では世界でも珍しい心停止ドナー膵島移植を行っている．生体ドナー膵島移植は 2005 年 1 月に京都大学で実施され世界で初めて成功した[2]．

　次に術式によって，①膵島単独移植（Islet Transplant Alone：ITA），②腎移植後膵島移植（Islet Transplant after Kidney：IAK），③膵島腎同時移植（Simultaneous Islet Kidney Transplant：SIK）に分類できる．通常 ITA が行われているが，最近 IAK による移植腎の保護効果が注目さ

れている．SIK は現在ほとんど行われていない．

膵島移植後合併症

　分離膵島を経門脈的に肝臓に移植するため，門脈閉塞の可能性がある．実際には，移植組織量を 10 mL 以下とし，さらにヘパリンを同時に投与することで，そのリスクを減らしている．他に肝臓の穿刺部位からの出血の可能性がある．総じて膵島移植は侵襲の少ない手技で行えるため，移植に関連した重篤な合併症はない．

世界の膵島移植の現況

　膵島移植は 1970 年代から実験的に行われていたが，当初はうまくいかなかった．ところが，2000 年にカナダのアルバータ大学からいわゆるエドモントンプロトコールが発表されて移植成績が飛躍的に向上し世界に普及した．このプロトコールが現在の臨床膵島移植の標準となっている．その主な特徴は，①免疫抑制剤にステロイドを使わずに，シロリムスと少量のタクロリムスを使用すること，②一人の患者に複数回の移植を行うこと，③腎機能が保たれている患者を対象とすること，である[3]．現在では 70 以上の施設で 700 人以上の患者が既に受けているが，膵島移植に関連した死亡症例は 1 例もなく，高い安全性が確認されている．

　2005 年にアルバータ大学における膵島移植後の長期成績が発表され，インスリン離脱率は移植後 5 年で約 10%と膵臓移植と比べてかなり低い結果であった．しかしながら，移植膵島の生着率（C-ペプチド陽性で判定）は 5 年で 80%と高く，再びインスリン注射が必要となった場合でも内因性のインスリン分泌がある限りは血糖

値の安定化を得ることができると報告された[4]．即ち，ほとんどの患者において移植した膵島は徐々にその数は減少するが，少なくとも移植後5年間は血糖の調節に貢献することが分かった．

この発表から，現在では膵島移植は血糖値の安定化を得ることができる安全性の高い治療法であると認識されている．しかしながら，インスリン離脱を目標とした場合には，現在の技術では複数回の移植が必要であること，長期間の維持が困難であるなどの限界がある．

日本の膵島移植の現況

日本では膵島移植は組織移植の範疇に入るため，脳死ドナーを用いることができず，日本組織移植学会が定めたガイドラインに基づいて心停止ドナー膵島移植を行っている．実施に際しては，膵・膵島移植研究会で定められた規則の下で行っている．2004年4月に京都大学で第1例目が実施され，2007年3月までに全国で17人に33回の移植が行われた．

京都大学ではこれまで10名の患者に計19回の移植を行った（うち1例は生体ドナー移植）．移植後は全例で必要インスリン量は減少し，特に複数回の移植を受けた7名中3名がインスリン治療から離脱することができた．また，1回の移植ではインスリン治療から離脱することができなくても，インスリンの基礎分泌補充量が減少し，血糖値の不安定性の指標であるM値とMAGEは著明に低下し，重症低血糖は消失することが示された[5]．

当初日本では，エドモントンプロトコールに則って腎機能が保たれている患者を対象にITAのみを実施してきた．2006年9月に膵・膵島移植研究会でIAKの実施が承認されてからは，3名の腎移植後患者に4回のIAKが行われている．

表．膵臓移植と膵島移植の比較

	膵臓移植	膵島移植
麻酔	全身麻酔	局所麻酔
侵襲度	大	小
移植回数	1回	2～3回
費用	保険診療	自費または研究費
拒絶診断	可	不可
移植成績		
インスリン離脱（5年）	60～70%	約10%

膵臓移植と膵島移植の選択について

膵臓移植と膵島移植のどちらを選ぶかについては，病期によるところが大きく，膵臓移植は糖尿病性腎不全（透析）患者に対して腎臓移植と同時に行われ（SPK），膵島移植はまだ腎機能が保たれている患者が対象（ITA）となるのが一般的である．しかしながら，腎機能が保たれている患者に膵臓移植（ITA）も行われている．糖尿病性腎不全であらかじめ腎移植を受けた患者に対しては膵臓移植（PAK）も膵島移植（IAK）も行われている．膵臓移植は全身麻酔下での手術を要し，局所麻酔下でカテーテルを用いて行える膵島移植に比べて侵襲度が大きい．しかしながら，1回の移植でインスリン離脱でき，移植後5年のインスリン離脱率は60～70%と膵島移植の約10%に比べて成績が格段に良い．膵島移植ではインスリン離脱するのに複数回の移植を必要とし，またインスリン離脱を維持するのが難しいが，血糖値の安定化は高率に得ることができる．費用については，膵臓移植の方が日本でも保険適応になっている点で有利である（表）．これらの膵臓移植と膵島移植のメリットとデメリットを患者に十分説明し，個々の事情に応じて選択してもらうことが重要である．ただし，重度の心疾患などがあり耐術性のない症

例，重篤な血管合併症のため膵臓移植適応から外れる症例，腹腔内感染が原因で移植膵臓を摘出した既往があり膵臓再移植では感染の再燃が予想される症例などは，膵島移植が良い適応となる．

文献

1) Gruessner AC, Sutherland DR : Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clinical Transplantation 19 ; 433-455, 2005.

2) Matsumoto S, Okitsu T, Iwanaga Y, et al : Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 365 (9471) ; 1642-1644, 2005.

3) Shapiro, A. M. J, Lakey J. R. T, Ryan E. A, et al : Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. NEJM 343 ; 230-238, 2000.

4) Ryan EA, Lakey JR, Shapiro AM, et al : Five-year follow-up after clinical islet transplantation. Diabetes 54 (7) ; 2060-2069, 2005.

5) Sassa M, Fukuda K, Matsumoto S, et al : A single transplantation of the islets can cause glycemic stability and reduction of basal insulin requirement. Diabetes Research and Clinical Practice 73 (3) ; 235-240, 2006.

Points

◆膵臓移植は手術侵襲が大きいが，高いインスリン離脱率を維持可能である．

◆膵島移植は安全性が高いが，インスリン離脱を長期間維持するのは困難である．しかし，血糖値の安定化を得ることはできる．

心停止ドナー膵島移植

岩永康裕[1]，興津輝[1]，米川幸秀[2]，川口義弥[2]，上本伸二[1,2]

1）京都大学医学部附属病院　臓器移植医療部
2）京都大学　肝胆膵・移植外科

Islet Transplantation using Donation after Cardiac Death Donor

Yasuhiro Iwanaga [1], Teru Okitsu [1], Yukihide Yonekawa [2], Yoshiya Kawaguchi [2],
Sinji Uemoto [1,2]

1) Kyoto University Hospital Transplant Unit
2) Kyoto University Department of Hepatobiliary, Pancreas and Transplant Surgery

1．はじめに

膵島移植は，膵臓から膵島を分離し移植するという細胞移植である。1型糖尿病等のインスリン依存状態糖尿病に対して，膵β細胞を補充し適正なインスリン分泌を再開することによって糖代謝を正常化させることを目的としている。

海外では脳死ドナーからの膵臓を用いているが，膵島移植は組織移植の範疇に入るため，日本では制度上脳死ドナーを用いることができない。そこで，心停止ドナー膵島移植を行なっている。膵島分離は脳死ドナー膵を用いても十分な膵島収量を得ることが一般的に困難であるが，いわゆる"マージナルドナー"である心停止ドナーの膵臓から膵島を分離することはさらに困難である。

本稿では，心停止ドナーを用いた本邦の膵島移植の現況と当院における取り組みについて述べる。

【キーワード】
膵島移植，膵島分離，マージナルドナー，
心停止ドナー，インスリン依存状態糖尿病

2．世界の膵島移植の状況

膵島移植は1970年代に実験医療として開始されたが，当初は，インスイリン注射からの離脱症例はなかった。膵島分離が難しく，十分な膵島収量を得られないことがその大きな原因であった。1988年にDr. Ricordiが大量の膵島を分離する方法（Ricordi法）を開発し[1]，翌年の1989年に初のインスリン離脱症例を出した。しかしながら移植成績は芳しくなく，しばらくは一部の施設でのみ行われる実験的治療法であった。膵島移植が世界中に広まったのは，2000年にカナダのアルバータ大学からエドモントンプロトコール[2]が発表されて移植成績が向上してからのことである。このプロトコールが現在の臨床膵島移植の標準となり，これまでに世界で60以上の移植施設で700人以上の患者が移植を受けている。

膵島移植の成績については，2005年にアルバータ大学から移植後5年間の成績が発表された。インスリン離脱率は移植後2年で約40%，5年で約10%であった（図1）。膵島の生着率（C-ペプチド0.3ng/ml以上で判定）については移植後5年でも80%あり，これらのインスリン基礎分泌がある人は，再びインスリン注射が必要となっても

A インスリン離脱率

B 膵島生着率

図1. 膵島移植の成績（アルバータ大学）

HbA1c：6％台と血糖値の安定化を維持できていた[3]。

マージナルドナーの定義ついて，ピッツバーグ大学の基準を引用すると，①年齢は45歳以上，②循環動態が不安定で，昇圧剤が単剤でDopamine>10μg/kg/minまたは2剤以上使用されている，③心停止ドナーのいずれかに該当するものとしている[4]。海外でのマージナルドナーを用いた膵島移植については，報告例が少ない。マイアミ大学では膵臓保存に二層法を使うことで50才以上のマージナルドナー膵を用いても膵島分離で十分な収量を得て移植を行なうことができた[5]。心停止ドナー膵島移植については，ペンシルバニア大学からの1例報告があるのみである[6]。

3．日本の膵島移植の状況

膵島移植は組織移植の範疇に入るため，日本では原則として心停止ドナーを用いている。ドナーの適応基準は，日本組織移植学会の「ヒト組織を利用する医療行為に関するガイドライン」[7]を遵守して感染症，悪性疾患などを除外し，さらに，膵・膵島移植研究会膵島移植班が定めた膵島移植実施マニュアル[8]に従って，①年齢は70歳以下，②温阻血時間は原則として30分以内が望ましい，③膵臓保存法はUW液による単純浸漬保存または二層法を用いることが望ましい，と定められている（表1）。

膵臓から分離した膵島を移植に供するか否かの判断基準 "新鮮膵島移植の基準" についても表2の通り膵島移植実施マニュアル[8]で定められている。すなわち，レシピエント体重あたり5,000IEQ/kg 以上の膵島収量があり，純度30% 以上，組織量10 ml 未満，viability 70% 以上，エンドトキシン5EU/kg 未満（患者体重），グラム染色陰性などの基準を満たした場合に新鮮膵島移植を行うこととされている。

膵島移植は一人につき3回まで行うことが可能で，2004年4月に本邦初症例が実施されてから

表1. 膵島移植ドナー適応基準

1. ドナー年齢は原則として70歳以下とする。

2. 心停止後から膵臓灌流開始までの許容時間（温阻血時間）は原則として30分以下とする。

3. 感染症等の除外項目は組織移植学会のガイドラインに準じて行なう。

4. 摘出膵保存法はUW液による単純浸漬保存または二層法を用いることが望ましい。

• 　家族から「膵島移植のための膵臓提供の承諾」が得られた場合、脳死ドナー、心停止ドナーから、ともに提供を受けることが出来る。いずれの場合も「膵島移植のための膵臓提供」は心停止後となる。

（文献(8)より引用）

表2．新鮮膵島移植の基準（参考）

分離膵島が以下の条件を満たすときに、新鮮膵島を移植する。

1. 膵島量 $\geq$ 5,000IE/kg(患者体重)以上

2. 純度 $\geq$ 30%

3. 組織量 $\leq$ 10ml

4. Viability $\geq$ 70%

5. Endotoxin $\leq$ 5EU/kg (患者体重)

6. グラム染色陰性

（文献(8)より引用）